Cooper Co (COO) AI Stock Analysis

• Market Cap: $13.69B
• Dividend Yield: N/A
• Average Volume (3M): 2.56M
• Price to Earnings (P/E): 34.0
• Beta (1Y): 0.81
• Revenue Growth: 6.35%
• EPS Growth: 12.94%
• Country: US
• Employees: 16,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.10
• Shares Outstanding: 198,808,910
• 10 Day Avg. Volume: 2,010,416
• 30 Day Avg. Volume: 2,559,176
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.20
• Enterprise Value/Revenue: 4.08
• Enterprise Value/Gross Profit: 6.09
• Enterprise Value/Ebitda: 15.12
• 1Y Price Target: $81.20
• Price Target Upside: 17.68% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 72 Outperform
• Price Target: $77.00 ▲(11.59% Upside)

Cooper Co's strong financial performance and positive developments in the MyDay product line are significant strengths. However, the stock's high valuation and challenges with Clarity orders and e-commerce in Asia Pacific present risks. The technical indicators suggest potential for upward movement, but the stock remains overvalued, impacting its overall attractiveness.

Positive Factors

Strong Free Cash Flow

Robust free cash flow enhances financial flexibility, allowing for strategic investments, debt reduction, and shareholder returns, supporting long-term growth.

MyDay Product Developments

Resolving manufacturing constraints and renewing contracts for MyDay products position COO for sustained growth and competitive advantage in the contact lens market.

Myopia Management Growth

Strong growth in Myopia management products like MiSight indicates a successful strategy in addressing a growing market need, supporting future revenue expansion.

Negative Factors

Clarity Product Challenges

Declining Clarity orders reflect shifting customer preferences and competitive pressures, potentially impacting revenue and market share if not addressed.

E-commerce Channel Weakness

Weakness in the Asia Pacific e-commerce segment could limit growth opportunities and necessitate strategic adjustments to capture online market potential.

PARAGARD Sales Decline

The decline in PARAGARD sales suggests volatility in demand and potential challenges in sustaining product performance, impacting revenue consistency.

Cooper Co Business Overview & Revenue Model

Company Description

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

How the Company Makes Money

Cooper Co generates revenue through multiple streams, including direct sales of its consumer goods to retailers and distributors, as well as online sales through its e-commerce platform. The company also earns income from B2B contracts, providing industrial supplies and services to various businesses. Additionally, COO has established strategic partnerships with major retailers, which helps enhance its market reach and brand visibility. Seasonal promotions and product launches further contribute to sales spikes, while ongoing investment in research and development ensures the company remains competitive and responsive to market demands.

Cooper Co Financial Statement Overview

Summary

Cooper Co exhibits strong financial health with robust revenue growth and stable profitability. The balance sheet is solid, with manageable leverage and a strong equity base. Cash flow generation is improving, although there is room for further optimization. The company is well-positioned for future growth, though monitoring cost pressures and enhancing profitability remain key focus areas.

Income Statement

Cooper Co has demonstrated strong revenue growth with a TTM increase of 1.44%, indicating robust demand for its products. The gross profit margin remains healthy at 65.73%, and the net profit margin is stable at 10.08%. EBIT and EBITDA margins are also solid, reflecting efficient operations. However, the slight decline in gross profit margin from the previous year suggests potential cost pressures.

Balance Sheet

The company's balance sheet is strong, with a manageable debt-to-equity ratio of 0.30, indicating prudent financial leverage. Return on equity is moderate at 4.97%, suggesting room for improvement in profitability. The equity ratio of 67.49% highlights a solid capital structure, providing stability.

Cash Flow

Cooper Co's cash flow performance is commendable, with a 12.57% growth in free cash flow, indicating improved cash generation capabilities. The operating cash flow to net income ratio of 0.81 suggests efficient cash conversion. However, the free cash flow to net income ratio of 0.50 indicates potential for further enhancement in cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.05B	3.90B	3.59B	3.31B	2.92B	2.43B
Gross Profit	2.71B	2.60B	2.36B	2.14B	1.96B	1.53B
EBITDA	1.09B	1.07B	885.90M	878.70M	823.90M	590.40M
Net Income	407.80M	392.30M	294.20M	385.80M	2.94B	238.40M
Balance Sheet
Total Assets	12.38B	12.32B	11.66B	11.49B	9.61B	6.74B
Cash, Cash Equivalents and Short-Term Investments	124.90M	107.60M	120.90M	138.20M	95.90M	115.90M
Total Debt	2.48B	2.58B	2.57B	2.76B	1.48B	2.06B
Total Liabilities	4.02B	4.23B	4.11B	4.32B	2.66B	2.91B
Stockholders Equity	8.35B	8.08B	7.55B	7.17B	6.94B	3.82B
Cash Flow
Free Cash Flow	411.90M	288.10M	215.00M	450.40M	524.20M	176.20M
Operating Cash Flow	816.30M	709.30M	607.50M	692.40M	738.60M	486.60M
Investing Cash Flow	-515.70M	-764.60M	-449.00M	-1.83B	-450.30M	-364.50M
Financing Cash Flow	-289.90M	39.20M	-173.90M	1.19B	-311.40M	-95.50M

Cooper Co Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 69.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COO, the sentiment is Negative. The current price of 69 is below the 20-day moving average (MA) of 71.27, below the 50-day MA of 69.24, and below the 200-day MA of 76.98, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 42.91 is Neutral, neither overbought nor oversold. The STOCH value of 12.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COO.

Cooper Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WST	76 Outperform	$20.64B	42.50	16.94%	0.31%	4.90%	-0.26%
COO	72 Outperform	$13.69B	33.97	5.01%	―	6.35%	12.94%
HOLX	69 Neutral	$16.52B	29.86	11.12%	―	1.74%	-25.29%
MASI	56 Neutral	$8.00B	―	-17.93%	―	-16.03%	-813.48%
BAX	53 Neutral	$9.22B	―	-4.70%	3.79%	-21.20%	-325.40%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATR	50 Neutral	$7.58B	18.52	15.80%	1.58%	2.50%	25.05%

Cooper Co Corporate Events

Cooper Companies Earnings Call: Balancing Growth and Challenges

The recent earnings call for Cooper Companies painted a picture of mixed sentiment, reflecting robust free cash flow and strong performance in the EMEA region, alongside exciting developments in the MyDay product line. However, the company faced challenges with revenue coming in below expectations, primarily due to a decline in Clarity orders and weakness in the Asia Pacific e-commerce segment. The overall sentiment was balanced, with positive prospects for MyDay and Myopia management, yet weighed down by immediate revenue challenges.

CooperCompanies Reports Strong Q3 2025 Performance

CooperCompanies, a global leader in the medical device industry, operates through its two main business units, CooperVision and CooperSurgical, focusing on contact lenses and women’s healthcare solutions, respectively. In its third quarter of 2025, CooperCompanies reported a 6% increase in revenue year-over-year, reaching $1,060.3 million. The company’s CooperVision unit saw a 6% rise in revenue, while CooperSurgical experienced a 4% increase. Despite a slight decrease in GAAP diluted earnings per share to $0.49, non-GAAP diluted EPS rose by 15% to $1.10, indicating strong operational performance. Key financial metrics highlighted include a gross margin of 65% and an operating margin of 17%, both slightly down from the previous year due to a product line exit at CooperSurgical. However, on a non-GAAP basis, the gross margin improved to 67%, and the operating margin rose to 26%, driven by efficiency gains and favorable foreign exchange impacts. The company also generated a robust free cash flow of $164.6 million. Looking ahead, CooperCompanies has raised its earnings guidance, anticipating improved revenue in the fourth quarter and fiscal year 2026, bolstered by the performance of its MyDAY® product line. The management remains confident in its strategy to deliver long-term shareholder value.